Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment
Key Points
Key points are not available for this paper at this time.
Abstract
clinicaltrials.gov Identifier: NCT01627249.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment | Synapse